GC
BCRX icon

Guggenheim Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Guggenheim Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,790
Closed -$112K – 1712
2024
Q3 		$112K Sell
14,790
-1,065
-7% -$8.1K ﹤0.01% 1825
2024
Q2 		$98K Buy
15,855
+34
+0.2% +$188 ﹤0.01% 1828
2024
Q1 		$80.4K Sell
15,821
-220
-1% -$1.24K ﹤0.01% 1853
2023
Q4 		$96.1K Sell
16,041
-106,281
-87% -$616K ﹤0.01% 1853
2023
Q3 		$866K Buy
122,322
+8,766
+8% +$63K 0.01% 1166
2023
Q2 		$799K Sell
113,556
-15,009
-12% -$120K 0.01% 1275
2023
Q1 		$1.07M Sell
128,565
-9,759
-7% -$93.9K 0.01% 1146
2022
Q4 		$1.59M Buy
138,324
+33,325
+32% +$416K 0.01% 943
2022
Q3 		$1.32M Sell
104,999
-24,724
-19% -$318K 0.01% 1010
2022
Q2 		$1.37M Buy
129,723
+17,693
+16% +$183K 0.01% 1076
2022
Q1 		$1.82M Sell
112,030
-13,065
-10% -$210K 0.01% 1068
2021
Q4 		$1.73M Buy
125,095
+111,531
+822% +$1.48M 0.01% 1124
2021
Q3 		$195K Buy
+13,564
New +$214K ﹤0.01% 2072
2015
Q1 		– Sell
-264,963
Closed -$3.22M – 3035
2014
Q4 		$3.22M Buy
264,963
+36,223
+16% +$400K 0.01% 1380
2014
Q3 		$2.24M Buy
228,740
+202,149
+760% +$2.48M 0.01% 1685
2014
Q2 		$339K Buy
26,591
+2,672
+11% +$26K ﹤0.01% 2726
2014
Q1 		$253K Buy
23,919
+6,309
+36% +$67.3K ﹤0.01% 2802
2013
Q4 		$134K Buy
17,610
+1,045
+6% +$6.62K ﹤0.01% 2925
2013
Q3 		$121K Sell
16,565
-3,467
-17% -$17.6K ﹤0.01% 2832
2013
Q2 		$31K Buy
+20,032
New +$34.6K ﹤0.01% 2946

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Guggenheim Capital's BCRX Position: Q4 2024 in Review

Guggenheim Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 14,790 shares — an estimated $112K sold.

Guggenheim Capital first reported a position in BCRX in Q2 2013 and held it in 20 quarters. The position peaked at $3.22M in Q4 2014. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Guggenheim Capital reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Guggenheim Capital sold 14,790 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $112K.
  • Guggenheim Capital first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Guggenheim Capital's BioCryst Pharmaceuticals position peaked at $3.22M in Q4 2014.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Guggenheim Capital's 13F filing for Q4 2024, filed 13 Feb 2025.